NCT00952081 - A Pilot Study to Evaluate Efficacy and Safety of Clevidipine in Neurosurgical Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2009

Primary Completion Date

December 31, 2009

Study Completion Date

February 28, 2010

Conditions

HypertensionBrain TumorEpilepsy

Interventions

DRUG

Clevidipine

Clevidipine (0.5 mg/ml in 20 % lipid solution) will be administered via peripheral vein using syringe pump; drug infusion will be initiated at 5 mg/hr (10ml/h) and titrated to effect up to a maximum rate of 32 mg/hr when SBP exceeds 130 mm Hg. The anesthesiologist will be allowed to administer the alternative antihypertensive treatment (e.g. labetalol, hydralazine) after achieving a maximum clevidipine infusion rate.

Trial Locations (1)

10016

NYU Langone Medical Center, Department of Anesthesiology, New York